Novartis AG (NVS)
137.16
-0.32
(-0.23%)
USD |
NYSE |
Sep 11, 16:00
140.19
+3.03
(+2.21%)
Pre-Market: 05:33
Novartis Price to Book Value : 6.044 for Sept. 11, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 6.044 |
| September 10, 2026 | 6.058 |
| September 09, 2026 | 6.058 |
| September 08, 2026 | 6.068 |
| September 04, 2026 | 7.050 |
| September 03, 2026 | 7.186 |
| September 02, 2026 | 7.159 |
| September 01, 2026 | 7.106 |
| August 31, 2026 | 6.700 |
| August 28, 2026 | 6.778 |
| August 27, 2026 | 6.815 |
| August 26, 2026 | 6.942 |
| August 25, 2026 | 7.050 |
| August 24, 2026 | 6.963 |
| August 21, 2026 | 7.000 |
| August 20, 2026 | 6.885 |
| August 19, 2026 | 7.064 |
| August 18, 2026 | 6.810 |
| August 17, 2026 | 6.696 |
| August 14, 2026 | 6.648 |
| August 13, 2026 | 6.686 |
| August 12, 2026 | 6.712 |
| August 11, 2026 | 6.813 |
| August 10, 2026 | 6.909 |
| August 07, 2026 | 6.889 |
| Date | Value |
|---|---|
| August 06, 2026 | 6.795 |
| August 05, 2026 | 6.805 |
| August 04, 2026 | 6.754 |
| August 03, 2026 | 6.771 |
| July 31, 2026 | 6.881 |
| July 30, 2026 | 6.982 |
| July 29, 2026 | 6.999 |
| July 28, 2026 | 7.044 |
| July 27, 2026 | 6.879 |
| July 24, 2026 | 6.830 |
| July 23, 2026 | 6.880 |
| July 22, 2026 | 6.745 |
| July 21, 2026 | 6.780 |
| July 20, 2026 | 6.590 |
| July 17, 2026 | 6.775 |
| July 16, 2026 | 6.73 |
| July 15, 2026 | 6.645 |
| July 14, 2026 | 6.626 |
| July 13, 2026 | 6.758 |
| July 10, 2026 | 6.788 |
| July 09, 2026 | 6.813 |
| July 08, 2026 | 6.838 |
| July 07, 2026 | 6.920 |
| July 06, 2026 | 6.852 |
| July 02, 2026 | 7.046 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 10.50 |
| GSK Plc | 4.157 |
| Johnson & Johnson | 7.527 |
| Eli Lilly & Co. | 31.01 |
Price to Book Value Related Metrics
| PE Ratio | 20.69 |
| PS Ratio | 4.818 |
| Price to Free Cash Flow | 17.61 |
| Price | 137.16 |
| Earnings Yield | 4.83% |
| Market Cap | 251.08B |
| Operating PE Ratio | 16.29 |
| Normalized PE Ratio | 19.28 |